A tough setback for AZ as major eye cancer hopeful flunks phase III

At one point, selumetinib was hailed as a potential blockbuster based on strong mid-stage survival data. 

By Nicole Gray • July 23, 2015

Roche renews commitment to R&D of two AD drugs

As the Alzheimer's research community bets bigger on the beta-amyloid theory, Roche has re-committed to two antibody drugs that target amyloid protein.

By Nicole Gray • July 23, 2015

Explore the Trendline➔

Oncology's research boom

More than one quarter of the medcines cleared by the FDA's main review office since 2015 have been cancer drugs, a tally that reflects the advent of cancer immunotherapy as well as continued progress in matching treatment to genetics.

By BioPharma Dive staff

A mixed bag: Biogen's & Lilly's hotly anticipated Alzheimer's data are inconclusive

Both companies' shares fell in early morning trading as the results proved far murkier than many had hoped.

By Sy Mukherjee • July 22, 2015

Promising stem-cell clinical trial results for rare lung disease

In the trial, reserachers evaluated the effect of genetically enhanced stem cell therapy on lung blood pressure levels in pulmonary arterial hypertension (PAH). 

By Nicole Gray • July 22, 2015

NEJM: Early HIV therapy delays AIDS-related events & death

In a clinical study, 1.8% of HIV-positive patients who received immediate treatment experienced a serious health outcome over a three-year period, compared with 4.1% of patients who delayed treatment.

By Nicole Gray • July 21, 2015

Researchers are about to launch the largest AIDS treatment trial ever

Researchers at UCSF are planning a 100-patient trial that determines whether very early treatment of HIV infection, followed by an interruption, can lead to a functional cure after promise in a French AIDS patient. 

By Nicole Gray • July 20, 2015

Bristol-Myers' rock star Opdivo continues to roll, this time in kidney cancer

An ongoing trial was stopped early after Opdivo proved more effective than everolimus in providing a survival advantage. 

By Nicole Gray • July 20, 2015

Amgen's leukemia drug excels in phase II for new indication

Amgen is going after a new indication for Blincyto (blinatumomab) and has reached some success.  

By Nicole Gray • July 20, 2015

Why some new drugs are truly earning the 'innovative' label

Many so-called innovative drug approvals rely on an established mode of action. So what makes a drug truly innovative?  

By Nicole Gray • July 16, 2015

ASCO scorecard upgrades rating for Lilly's Alimta

Alimta (pemetrexed) fell short on an initial scorecard, but its score improved when ratings were focused on a more specific form of lung cancer.

By Nicole Gray • July 16, 2015

J&J/Bavarian Nordic launching phase II Ebola vaccine trial

Healthy volunteers in England and France will be tested with the vaccine to assess safety, tolerabilty and immunogenicity. 

By Nicole Gray • July 16, 2015

Roche's PD-L1 drug slows bladder cancer growth in trials

Atezolizumab shrank tumors in patients with advanced or metastatic urothelial bladder cancer.

By Nicole Gray • July 13, 2015

Study: Type 2 diabetes linked with cognitive decline

According to a new study, patients diagnosed with diabetes experience significant cognitive decline within a two-year period.

By Nicole Gray • July 13, 2015

A 21st century diabetes option: Will Oramed be first to market with oral insulin?

According to Oramed’s COO, Josh Hexter, oral insulin represents a first-in-class treatment option for diabetes and promises to be a truly disruptive force in a challenging therapeutic area.

By Nicole Gray • July 10, 2015

Another Indian CRO in hot water, this time with the WHO

According to the World Health Organization, Chennai-based Quest Life Sciences egregiously mishandled clinical trial results.

By Nicole Gray • July 8, 2015

J&J moves HIV vax to human trials after 50% protection rate in monkeys

Six out of 12 monkeys who received the vaccine were protected from HIV infection. 

By Nicole Gray • July 6, 2015

Another Roche Alzheimer's drug disappoints

Sembragiline did not demonstrate cognitive benefit in treated patients after 52 weeks. 

By Nicole Gray • July 6, 2015

Roche impresses with strong phase III data for MS drug candidate

But hefty competitors like Novartis and Biogen loom on the horizon.

By Nicole Gray • July 1, 2015

Celgene & Juno just struck a blockbuster $1B collab deal—but does it make sense?

Some industry observers are raising their eyebrows at the sheer amount of cash that Celgene is pumping into the deal. 

By Nicole Gray • June 30, 2015

With new Cosentyx data, Novartis slated to nab huge psoriasis market share

The therapy, approved in January for plaque psoriasis, has now also shown rapid and long-lasting efficacy for psoriatic arthritis. And the firm could rake in $4 billion to $5 billion in sales as a result.

By Sy Mukherjee • June 29, 2015

Lilly's data mining may pay off with nearly-abandoned Alzheimer's drug

In 2012, researchers at Eli Lilly were ready to give up on solanezumab, an experimental drug for Alzheimer's disease. But results from two studies changed their minds.

By Nicole Gray • June 29, 2015

Bristol-Myers calls it quits on any new virology R&D programs

But the company's ongoing programs in virology will remain in place. 

By Nicole Gray • June 26, 2015

Study: Combo Rx regimen can treat bipolar depression

Cyclurad, a combination of Ketamine, the mood stabilizer Lurasidone, and a tubreculosis drug, has long-term efficacy in hard-to-treat bipolar depression, according to a study.

By Nicole Gray • June 25, 2015

Alcobra flops as placebo beats its drug in phase II

In clinical trials, MDX was tested for treatment of both ADHD and fragile X syndrome and failed to meet primary endpoints.

By Nicole Gray • June 25, 2015

The early winners and losers in ASCO's highly anticipated cancer drug scorecard

ASCO's drug scorecard is designed to simplify therapeutic decision-making by comparing survival data for different regimens with costs and side effects. 

By Nicole Gray • June 24, 2015